Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | ADH5 | P11766 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618874 | 0.87 | ALDH1A1 (0.43) | ALDH1A1EGLN3TBXAS1FAAHMGLL | |
| SCHEMBL173415 | 0.80 | — | — | |
| SCHEMBL12667290 | 0.79 | FAAH (0.41) | ALDH1A1EGLN3TBXAS1FAAHMGLL | |
| SCHEMBL10405960 | 0.79 | CYP3A4 (0.39) | ALDH1A1EGLN3TBXAS1FAAHMGLL | |
| SCHEMBL25507691 | 0.79 | CYP3A4 (0.39) | ALDH1A1EGLN3TBXAS1FAAHMGLL | |
| SCHEMBL28775118 | 0.78 | — | — | |
| SCHEMBL29083648 | 0.78 | — | — | |
| Bromide SCHEMBL28355066 | 0.78 | — | — | |
| Strontium SCHEMBL2839675 | 0.78 | — | — | |
| SCHEMBL29083659 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | claimed |
| EP-1150961-B1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | claimed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | claimed |
| CN-1346349-A | Pyrazoelcarboxylic acid derivatives, their preparation, pharmaceutical compositions containing | SANOFI SYNTHELABO (FR) | 2002-04-24 | — | — | CN | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-104710305-B | A kind of synthetic method of 2-(2-hydroxy phenyl)-2-fluoroacetic acid ester | 常熟市联创化学有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-104710305-A | Synthetic method for 2-(2-hydroxyphenyl)-2-oxyacetate | CHANGSHU LEAGUE CHEMICAL CO LTD | 2015-06-17 | — | — | CN | disclosed |
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | disclosed |
| US-7019026-B1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2006-03-28 | — | — | US | disclosed |
| EP-1214325-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2005-11-09 | — | — | EP | disclosed |
| US-6951878-B2 | Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2005-10-04 | — | — | US | disclosed |
| EP-1080095-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1080068-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1062199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046267-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046236-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| US-5776964-A | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-07 | — | — | US | disclosed |
| US-5521206-A | HYPOTENSIVE AGENTS, TREATMENT OF ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | ALDH1A1 546/4885EGLN3 2336/4885TBXAS1 737/4885 |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | ALDH1A1 546/4885EGLN3 2336/4885TBXAS1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.